miR-141-3p alleviates ulcerative colitis by targeting SUGT1 to inhibit colonic epithelial cell pyroptosis

References

• Eisenstein M. Ulcerative colitis: towards remission. Nature. 2018;563(7730):1.
   Web of Science ®Google Scholar
• Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606–12.
   PubMed Web of Science ®Google Scholar
• Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–170.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74.
   PubMed Web of Science ®Google Scholar
• Ahluwalia B, Moraes L, Magnusson MK, et al. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018;53(4):379–389.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205–217.
   PubMed Web of Science ®Google Scholar
• Lv Q, Xing Y, Liu J, et al. Lonicerin targets EZH2 to alleviate ulcerative colitis by autophagy-mediated NLRP3 inflammasome inactivation. Acta Pharm Sin B. 2021;11(9):2880–2899.
   PubMed Web of Science ®Google Scholar
• Tong L, Hao H, Zhang Z, et al. Milk-derived extracellular vesicles alleviate ulcerative colitis by regulating the gut immunity and reshaping the gut microbiota. Theranostics. 2021;11(17):8570–8586.
   PubMed Web of Science ®Google Scholar
• Zhao N, Di B, Xu LL. The NLRP3 inflammasome and COVID-19: activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev. 2021;61:2–15.
   PubMed Web of Science ®Google Scholar
• Hu R, Wang MQ, Ni SH, et al. Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-kappaB/NLRP3 signaling pathway in AGEs-induced HUVECs. Eur J Pharmacol. 2020;867:172797.
   PubMed Web of Science ®Google Scholar
• Munoz-Planillo R, Kuffa P, Martinez-Colon G, et al. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38(6):1142–1153.
   PubMed Web of Science ®Google Scholar
• Sun L, Ma W, Gao W, et al. Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome. Cell Death Dis. 2019;10(8):542.
   PubMedGoogle Scholar
• Tan Y, Zhang M, Pan Y, et al. Suppression of the caspase-1/GSDMD-mediated pyroptotic signaling pathway through dexamethasone alleviates corneal alkali injuries. Exp Eye Res. 2022;214:108858.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu X, Shi H, et al. NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases. Clin Transl Med. 2020;10(1):91–106.
   PubMed Web of Science ®Google Scholar
• Steiner A, Reygaerts T, Pontillo A, et al. Recessive NLRC4-autoinflammatory disease reveals an ulcerative colitis locus. J Clin Immunol. 2022;42(2):325–335.
   PubMed Web of Science ®Google Scholar
• Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ. 2019;26(1):99–114.
   PubMed Web of Science ®Google Scholar
• Karmakar M, Minns M, Greenberg EN, et al. N-GSDMD trafficking to neutrophil organelles facilitates IL-1beta release independently of plasma membrane pores and pyroptosis. Nat Commun. 2020;11(1):2212.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Bartel DP. Metazoan MicroRNAs. Cell. 2018;173(1):20–51.
   PubMed Web of Science ®Google Scholar
• Paul P, Chakraborty A, Sarkar D, et al. Interplay between miRNAs and human diseases. J Cell Physiol. 2018;233(3):2007–2018.
   PubMed Web of Science ®Google Scholar
• Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35(2):180–188.
   PubMed Web of Science ®Google Scholar
• van der Ree MH, de Vree JM, Stelma F, et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet. 2017;389(10070):709–717.
   PubMed Web of Science ®Google Scholar
• Liu C, Yan X, Zhang Y, et al. Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy. J Nanobiotechnology. 2022;20(1):206.
   PubMed Web of Science ®Google Scholar
• Wei YY, Fan YM, Ga Y, et al. Shaoyao decoction attenuates DSS-induced ulcerative colitis, macrophage and NLRP3 inflammasome activation through the MKP1/NF-kappaB pathway. Phytomedicine. 2021;92:153743.
   PubMed Web of Science ®Google Scholar
• Adamowicz M, Milkiewicz P. Kempinska-Podhorodecka A. 5-aminosalicylic acid inhibits the expression of oncomiRs and pro-inflammatory microRNAs: an in vitro study. J Physiol Pharmacol. 2021;72(4):529–535.
   Web of Science ®Google Scholar
• Li H, Xuan J, Zhang W, et al. Long non-coding RNA SNHG5 regulates ulcerative colitis via microRNA-375/janus kinase-2 axis. Bioengineered. 2021;12(1):4150–4158.
   PubMed Web of Science ®Google Scholar
• Lu JW, Rouzigu A, Teng LH, et al. The construction and comprehensive analysis of inflammation-related ceRNA networks and tissue-infiltrating immune cells in ulcerative progression. Biomed Res Int. 2021;2021:6633442.
   PubMed Web of Science ®Google Scholar
• Cordes F, Demmig C, Bokemeyer A, et al. MicroRNA-320a monitors intestinal disease activity in patients with inflammatory bowel disease. Clin Transl Gastroenterol. 2020;11(3):e00134.
   PubMedGoogle Scholar
• Dubois-Camacho K, Diaz-Jimenez D, De la Fuente M, et al. Inhibition of miR-378a-3p by inflammation enhances IL-33 levels: a novel mechanism of alarmin modulation in ulcerative colitis. Front Immunol. 2019;10:2449.
   PubMed Web of Science ®Google Scholar
• Yan S, Yue Y, Wang J, et al. LINC00668 promotes tumorigenesis and progression through sponging miR-188-5p and regulating USP47 in colorectal cancer. Eur J Pharmacol. 2019;858:172464.
   PubMed Web of Science ®Google Scholar
• Pekow J, Meckel K, Dougherty U, et al. Increased mucosal expression of miR-215 precedes the development of neoplasia in patients with long-standing ulcerative colitis. Oncotarget. 2018;9(29):20709–20720.
   PubMedGoogle Scholar
• Feng X, Wang H, Ye S, et al. Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IkappaBalpha. PLoS One. 2012;7(12):e52782.
   PubMed Web of Science ®Google Scholar
• Patankar JV, Becker C. Cell death in the gut epithelium and implications for chronic inflammation. Nat Rev Gastroenterol Hepatol. 2020;17(9):543–556.
   PubMed Web of Science ®Google Scholar
• Cai M, Chen S, Hu W. MicroRNA-141 is involved in ulcerative colitis pathogenesis via aiming at CXCL5. J Interferon Cytokine Res. 2017;37(9):415–420.
   PubMed Web of Science ®Google Scholar
• Fasseu M, Treton X, Guichard C, et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One. 2010;5(10):e13160.
   PubMed Web of Science ®Google Scholar
• Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology. 2008;135(5):1624–1635 e1624.
   PubMed Web of Science ®Google Scholar
• Lu X, Yu Y, Tan S. The role of the miR-21-5p-mediated inflammatory pathway in ulcerative colitis. Exp Ther Med. 2020;19(2):981–989.
   PubMed Web of Science ®Google Scholar
• Yan H, Zhang X, Xu Y. Aberrant expression of miR-21 in patients with inflammatory bowel disease: a protocol for systematic review and meta analysis. Medicine (Baltimore). 2020;99(17):e19693.
   PubMed Web of Science ®Google Scholar
• Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 2014;1319(1):82–95.
   PubMed Web of Science ®Google Scholar
• Nizami S, Arunasalam K, Green J, et al. Inhibition of the NLRP3 inflammasome by HSP90 inhibitors. Immunology. 2021;162(1):84–91.
   PubMed Web of Science ®Google Scholar
• Piippo N, Korhonen E, Hytti M, et al. Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome. Sci Rep. 2018;8(1):6720.
   PubMed Web of Science ®Google Scholar
• Venegas C, Heneka MT. Inflammasome-mediated innate immunity in Alzheimer’s disease. Faseb J. 2019;33(12):13075–13084.
   PubMed Web of Science ®Google Scholar
• Rathinam VA, Vanaja SK, Waggoner L, et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell. 2012;150(3):606–619.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang H, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10(2):128.
   PubMed Web of Science ®Google Scholar
• Burdette BE, Esparza AN, Zhu H, et al. Gasdermin D in pyroptosis. Acta Pharm Sin B. 2021;11(9):2768–2782.
   PubMed Web of Science ®Google Scholar